Market closed
Viking Therapeutics/$VKTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Viking Therapeutics
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Ticker
$VKTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
31
Website
VKTX Metrics
BasicAdvanced
$3.7B
-
-$0.93
1.00
-
Price and volume
Market cap
$3.7B
Beta
1
52-week high
$99.41
52-week low
$21.26
Average daily volume
3.8M
Financial strength
Current ratio
36.467
Quick ratio
36.225
Long term debt to equity
0.083
Total debt to equity
0.135
Interest coverage (TTM)
-1,395.50%
Management effectiveness
Return on assets (TTM)
-12.68%
Return on equity (TTM)
-15.50%
Valuation
Price to book
4.09
Price to tangible book (TTM)
4.09
Price to free cash flow (TTM)
-47.851
Growth
Earnings per share change (TTM)
2.22%
3-year earnings per share growth (CAGR)
9.77%
What the Analysts think about VKTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Viking Therapeutics stock.
VKTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
VKTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
VKTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Viking Therapeutics stock?
Viking Therapeutics (VKTX) has a market cap of $3.7B as of January 29, 2025.
What is the P/E ratio for Viking Therapeutics stock?
The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of January 29, 2025.
Does Viking Therapeutics stock pay dividends?
No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of January 29, 2025.
When is the next Viking Therapeutics dividend payment date?
Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Viking Therapeutics?
Viking Therapeutics (VKTX) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.